We report the successful treatment of three patients with ANCA-associated vasculitis aged 79, 80, and 80 years. We also review other published reports of treatment in the elderly and discuss complications of treatment with emphasis on elderly patients.
The systemic vasculitides are rare disorders. Their classification is based on histopathology, size of vessel involved and clinical symptomatology. Many patients present with overlapping features of different vasculitides. A subgroup of vasculitides (Wegener's granulomatosis, microscopic polyarteritis, Churg Strauss syndrome) is strongly associated with circulating anti-neutrophil cytoplasmic antibody (ANCA). The increasing availability of the ANCA assay followed by characteristic biopsy has aided in the diagnosis of these rare conditions. Untreated Wegener's granulomatosis/microscopic polyangiitis has a poor prognosis. For example, Wegener's granulomatosis has a mean survival of only five months with a one year survival of only 20%.' In recent years, treatment with immunosuppression has radically altered prognosis. 2 To highlight diagnosis and treatment in the elderly we report the successful treatment of three patients with ANCA-associated vasculitis aged 79, 80, and 80 years. We also review other published reports of treatment in the elderly and discuss complications of treatment with emphasis on elderly patients. 
Case 2
An 80-year-old woman with a long-standing history of joint pains, impaired hearing and a unilateral bloody nasal discharge presented with a three-week history of dyspnoea, haemoptysis and right-sided pleuritic chest pain.
Initial investigations revealed a mild microcytic anaemia with haemoglobin of 9.5 g/dl; mean corpuscular volume of 79.6 fl, and erythrocyte sedimentation rate of 118 mm/h. There was evidence of renal impairment with urea of 33.8 mmol/l, creatinine 339 yumol/l and creatinine clearance 5.1 ml/min. Urine examination revealed haematuria, proteinuria (0.63 g/24 h) and the presence of granular casts. Small bilateral pleural effusions were present on the chest X-ray. Serum was strongly positive for cANCA. Renal histology showed a focal segmental necrotising glomerulonephritis with occasional crescents and a vasculitis consistent with Wegener's granulomatosis. A 1-cm diameter ulcerated area was seen on the right side of the nasal septum.
The patient's symptoms dramatically improved on prednisolone 40 mg/day and cyclophosphamide at 100 mg/day.
At six months the patient remains well on cyclophosphamide 100 mg/day and prednisolone 20 mg alternate days, although a degree of renal failure persists (urea 14.1 mmol/l, creatinine 225 Mumol/l).
Case 3
A 79-year-old man with a history of longstanding hypertension, joint pains, atypical chest pain and impaired hearing presented with a one-week history of severe polyarthralgia, haemoptysis, haematuria and a vasculitic rash.
Investigations demonstrated a haemoglobin of 12.5 g/dl, mean corpuscular volume of 91 fl, and an erythrocyte sedimentation rate of 59 mm/h. There was mild renal impairment with a urea of 8.1 mmol/l, creatinine of 134 !smol/l and urinalysis showed blood and protein (less than 0.08 g/l). Linear subsegmental collapse at both bases was present on the chest X-ray.
An initial diagnosis of Wegener's granulomatosis/ANCA-positive vasculitis was made and prednisolone 40 mg/day and cyclophosphamide 100 mg/day were commenced. The circulating cANCA was strongly positive and renal biopsy was subsequently performed. This showed minor glomerulosclerosis only, however the biopsy was performed several days after starting steroid treatment, raising the possibility that histology was altered by therapy.
The patient showed a dramatic response with resolution of all his symptoms and an improvement both biochemically and immunologically.
At six months the patient remains well with minimal renal impairment (urea of 9.5 mmol/l; creatinine of 127 Mmol/l) on prednisolone 10 mg daily. Cyclophosphamide was stopped at two months post diagnosis because the patient felt it was making him unwell though there was no objective evidence of cyclophosphamide toxicity. He refused to take azathioprine.
Discussion
The indirect immunofluorescent ANCA assay gives two patterns; cANCA and pANCA (perinuclear staining). Wegener's granulomatosis is usually associated with cANCA, whilst microscopic polyangiitis is associated with pANCA. pANCA can also be seen in a wide variety of inflammatory disorders.3 In vasculitis, however, pANCA is usually associated with specificity for myeloperoxidase whereas this is not the case in inflammatory disorders and thus it is obligatory to perform an antimyeloperoxidase EUISA in association with ANCA immunofluorescence. Given its association with other disorders, the presence of ANCA is not enough to make the diagnosis of vasculitis. The diagnosis should be confirmed by biopsy. All our patients had cANCA on indirect immunofluorescence. In view of the absence of granulomatous change on biopsy, these patients have been given the diagnosis of 'ANCA associated vasculitis'. This is in accordance with recent consensus guidelines on vasculitis nomenclature. 
Drug toxicity is a major problem. Cyclophosphamide has well-documented side-effects, mainly involving the bone marrow, bladder and reproductive organs (box 2).12l1 In the study of HofEman et al, bladder cancer developed as early as seven months following treatment with cyclophosphamide while two patients developed lymphoma at 1.5 and 8.6 years and myelodysplasia occurred in three patients at 1.6, 9.6 and 13 years. Thus, the risk of malignancy is still a pertinent problem in the elderly.
Predisposition to infection is a significant problem. Hoffman et al found 73 patients (46%) had episodes of serious infection over 1229 patient years.2 As well as bacterial infection, there was a 20-fold increase in herpes zoster whilst on cyclophosphamide and prednisolone. Cyclophosphamide can predispose to infection by causing bone marrow suppression and neutropenia, and by interfering with lymphocyte function. Azathioprine predisposes less to malignancy and infection than cyclophosphamide."l'l Prednisolone has been shown to be the most significant factor in cases of severe infection on immunosuppression."3 Fatal disease with cytomegalovirus (CMV) and Pneumocystis carinii has also been documented. 13 Elderly patients have a reduced immune response, with both impairment of cellmediated immunity and a reduction in humoral immunity.'4",5 Therefore elderly patients may be at greater risk from immunosuppression but may also need proportionally less in terms of type, dose, and duration.
The consequences of immunosuppression in the elderly have been looked at in the field of transplantation.'5"6 Elderly patients have fewer rejection episodes with an increase in lifethreatening infection. Less immunosuppression is advocated, but no randomised controlled trials support this. Similarly there are no controlled trials comparing treatments of vasculitis in the elderly. In general terms, the use of the least toxic drugs for the shortest periods should be considered. This must be balanced with the high rate of relapse which would mean a repeat period of intense immunosuppression with associated risks. Therefore, switching from cyclophosphamide to azathioprine once in remission and early tapering of steroids should be considered. The associated use of antimicrobial prophylaxis (eg, cotrimoxazole and acyclovir or gancyclovir) should also be 
